Wyeth Pharmaceuticals and Trubion Pharmaceuticals, Inc. have formed a strategic alliance for the discovery, development and commercialization of novel biopharmaceutical products to treat inflammatory disease and cancer. The alliance will utilize Trubion’s proprietary Small Modular Immunopharmaceutical (SMIP) technology. SMIPs are smaller than antibodies and can reach sites unavailable to larger molecules therefore the medicine is metabolized more slowly by the body suggesting less frequent...